![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
C21 (buloxibutid) is an angiotensin II type 2 receptor agonist, which is currently being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Lead Product(s): Buloxibutid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2024
Details:
C21 is an angiotensin II type 2 receptor agonist, which s being developed for the treatment endothelial dysfunction (reflecting blood vessel health) in patients with type-2-diabetes-mellitus.
Lead Product(s): Buloxibutid
Therapeutic Area: Endocrinology Product Name: C21
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
C21 is a small molecule compound, which is in clinical development for the treatment of IPF and COVID-19. The experimental programme will assess the potential of C21 for addressing fibrosis, inflammation and vasculopathy in a variety of diseases such as IPF.
Lead Product(s): Buloxibutid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The AIR trial1 is an open label single arm phase 2 trial in treatment naïve IPF patients in which 100 mg of C21 (VP01) was administered twice daily for 24 weeks with an optional 12-week extension.
Lead Product(s): VP01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orphan Reach
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2022
Details:
C106 is first of four advanced candidate drugs from VP03 program to enter clinical trials. C106 and the three additional candidates are small molecules with high affinity for AT2R and intended for indications also outside rare lung disease.
Lead Product(s): CAS 138564-60-0
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C106
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
The first candidate in the VP03 program, new AT2R agonist C106, shows high selectivity for AT2R and good activity in reducing TGFb in human tissue with patent protection to 2041, is ready to enter a phase 1 trial.
Lead Product(s): CAS 138564-60-0
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VP03
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emeriti Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Details:
With these results, the company initiates the planning of AIR 2, a double-blind controlled phase 2 dose-finding study to confirm these results and accelerate the development of C21 in parallel to completing the AIR trial.
Lead Product(s): VP01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2022
Details:
The results showed nearly 50% reduction in lung injury in the C21 group compared with the placebo group suggest that C21 could accelerate recovery and it is currently being evaluated in a phase 3 trial in COVID-19 patients.
Lead Product(s): VP01
Therapeutic Area: Infections and Infectious Diseases Product Name: C21
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the “protective arm” of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage.
Lead Product(s): VP01
Therapeutic Area: Infections and Infectious Diseases Product Name: C21
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
C21 is first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor agonist. C21 on respiratory function in COVID-19 was documented in recent phase 2 trial showing that C21 reduced need for supplemental oxygen in hospitalized patients by 90%.
Lead Product(s): VP01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021